EVEREST ORGANICS
|
EVEREST ORGANICS Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -1.33 | 0.17 | -0.23 | 1.43 | 17.14 |
| CEPS(Rs) | 4.81 | 7.42 | 5.36 | 6.18 | 21.36 |
| DPS(Rs) | - | - | - | 0.50 | 1.50 |
| Book NAV/Share(Rs) | 71.00 | 57.30 | 57.77 | 58.50 | 58.22 |
| Tax Rate(%) | 60.21 | 77.20 | 302.67 | 34.24 | 20.60 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 3.94 | 4.85 | 0.45 | 2.79 | 11.02 |
| EBIT Margin(%) | 1.07 | 2.68 | 1.63 | 2.10 | 9.90 |
| Pre Tax Margin(%) | -1.78 | 0.27 | 0.04 | 0.76 | 8.33 |
| PAT Margin (%) | -0.71 | 0.06 | -0.09 | 0.50 | 6.61 |
| Cash Profit Margin (%) | 2.56 | 2.62 | 2.06 | 2.15 | 8.24 |
| Performance Ratios | |||||
| ROA(%) | -0.57 | 0.06 | -0.10 | 0.73 | 10.73 |
| ROE(%) | -2.25 | 0.30 | -0.39 | 2.45 | 33.96 |
| ROCE(%) | 1.76 | 6.03 | 3.71 | 6.25 | 33.76 |
| Asset Turnover(x) | 0.81 | 1.06 | 1.10 | 1.47 | 1.62 |
| Sales/Fixed Asset(x) | 1.70 | 2.18 | 2.17 | 2.65 | 2.65 |
| Working Capital/Sales(x) | 22.86 | -21.14 | -40.94 | 43.31 | 17.44 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.59 | 0.46 | 0.46 | 0.38 | 0.38 |
| Receivable days | 188.66 | 142.15 | 126.69 | 94.48 | 83.54 |
| Inventory Days | 89.08 | 72.92 | 77.14 | 58.99 | 53.09 |
| Payable days | 382.32 | 302.90 | 261.92 | 180.39 | 188.38 |
| Valuation Parameters | |||||
| PER(x) | - | 659.77 | - | 121.57 | 13.41 |
| PCE(x) | 52.38 | 15.47 | 17.74 | 28.14 | 10.76 |
| Price/Book(x) | 3.55 | 2.00 | 1.65 | 2.97 | 3.95 |
| Yield(%) | - | - | - | 0.29 | 0.65 |
| EV/Net Sales(x) | 1.79 | 0.75 | 0.69 | 0.89 | 1.13 |
| EV/Core EBITDA(x) | 36.15 | 12.53 | 16.13 | 20.51 | 8.58 |
| EV/EBIT(x) | 146.84 | 24.49 | 37.35 | 36.59 | 9.99 |
| EV/CE(x) | 2.43 | 1.44 | 1.30 | 1.00 | 2.95 |
| M Cap / Sales | 1.53 | 0.47 | 0.42 | 0.70 | 1.01 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -19.15 | 7.75 | -8.50 | 10.18 | 8.58 |
| Core EBITDA Growth(%) | -33.38 | 50.80 | -8.86 | -63.86 | 15.29 |
| EBIT Growth(%) | -67.96 | 78.76 | -29.79 | -76.41 | 17.14 |
| PAT Growth(%) | -1,026.94 | 176.40 | -115.93 | -91.66 | 25.86 |
| EPS Growth(%) | -863.68 | 176.40 | -115.93 | -91.66 | 25.86 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.69 | 1.26 | 1.12 | 0.83 | 0.49 |
| Current Ratio(x) | 1.06 | 0.93 | 0.96 | 1.05 | 1.15 |
| Quick Ratio(x) | 0.73 | 0.66 | 0.62 | 0.68 | 0.73 |
| Interest Cover(x) | 0.38 | 1.11 | 1.03 | 1.56 | 6.30 |
| Total Debt/Mcap(x) | 0.20 | 0.63 | 0.68 | 0.28 | 0.12 |
Compare Financial Ratios of peers of EVEREST ORGANICS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| EVEREST ORGANICS | ₹389.9 Cr | -0.7% | -19.6% | 51% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹390,828.0 Cr | 1.2% | -5.3% | -5.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹158,227.0 Cr | -3.9% | -6% | 11.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹135,045.0 Cr | 0.9% | 3.7% | 20.5% | Stock Analytics | |
| CIPLA | ₹105,961.0 Cr | -1.2% | -12.6% | -6.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,682.5 Cr | -3.4% | -5.7% | 0.3% | Stock Analytics | |
EVEREST ORGANICS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EVEREST ORGANICS | -0.7% |
-19.6% |
51% |
| SENSEX | -0.2% |
-4.2% |
8.4% |
You may also like the below Video Courses
